Kt Corporation ADR Stock
Your prediction
Kt Corporation ADR Stock
Kt Corporation ADR shows a slight decrease today, losing -€0.100 (-0.630%) compared to yesterday.
Pros and Cons of Kt Corporation ADR in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Kt Corporation ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Kt Corporation ADR | -0.630% | 1.923% | 4.605% | -7.558% | 0.633% | 41.964% | 25.197% |
| Freenet AG | 0.590% | -1.724% | 0.335% | -15.167% | -18.847% | 9.716% | 18.986% |
| Philippine Long Distance Telephone Company ADR | -1.180% | 0.000% | 2.454% | -13.918% | -7.222% | -19.712% | -17.327% |
| Telekom Austria AG | 0.600% | -0.978% | 1.200% | 7.090% | 12.695% | 50.820% | 33.862% |
News
Kymera Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better.
- KT-621 atopic dermatitis trial enrollment is complete about six months ahead of schedule, with top-line
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Chief Executive Officer Nello Mainolfi sold 50,000 shares of Kymera Therapeutics (NASDAQ:KYMR) on July 7, 2026, for total proceeds of about $6.0 million, according to an SEC Form 4 filing.
Kymera
Why Kymera Therapeutics Stock Popped This Week
This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch